Latest news with #RM70mil
The Star
6 days ago
- Business
- The Star
AmBank approves RM70mil financing for Sunview
AmBank Group SVP, commercial banking 1, business banking Edmund Tay (seated, left) and Sunview group executive director and group chief operating officer Chow Kian Hung (seated, right) together with (from left) AmBank Group head of commercial banking 1, business banking Yeow Swee Yun, AmBank Group managing director of business banking Christopher Yap and Sunview group executive director and group chief executive officer HP Ong. PETALING JAYA: AmBank Group, through AmBank Islamic Bhd, has approved banking facilities amounting to RM70mil for Fabulous Sunview Sdn Bhd (FSSB), a wholly owned subsidiary of Sunview Group Bhd . In a statement, the bank said the financing would partly fund the construction of a 29.99MWac ground-mounted photovoltaic solar power plant in Sungai Petani, Kuala Muda, Kedah. The project was awarded by Dayasinar Energy Sdn Bhd under the Corporate Green Power Programme. The project with a contract amounting to RM98.29mil will be executed by FSSB where it includes design, procurement, erection, connection, commissioning and testing as well as supply of equipment for the construction of a ground mounted photovoltaic solar generation facility. 'We are pleased to support FSSB and Sunview Group in this initiative. Looking ahead, we remain committed to strengthening our contribution to Malaysia's renewable energy ecosystem,' AmBank Group managing director, business banking Christopher Yap said.
The Star
7 days ago
- Business
- The Star
Ambank approves RM70mil financing for Sunview's 29.99MW solar project
AmBank Group SVP, commercial banking 1, business banking Edmund Tay (seated, left) and Sunview group executive director and group chief operating officer Chow Kian Hung (seated, right) together with (from left) AmBank Group head of commercial banking 1, business banking Yeow Swee Yun, AmBank Group managing director of business banking Christopher Yap and Sunview group executive director and group chief executive officer HP Ong. KUALA LUMPUR: AmBank Group, through AmBank Islamic Bhd, has approved banking facilities amounting to RM70mil for Fabulous Sunview Sdn Bhd (FSSB), a wholly owned subsidiary of Sunview Group Bhd . In a statement, the bank said the financing would partly fund the construction of a 29.99MWac ground-mounted photovoltaic solar power plant in Sungai Petani, Kuala Muda, Kedah. The project was awarded by Dayasinar Energy Sdn Bhd under the Corporate Green Power Programme (CGPP). The project with a contract amounting to RM98.29mil will be executed by FSSB where it includes design, procurement, erection, connection, commissioning and testing as well as supply of equipment for the construction of a ground mounted photovoltaic (PV) solar generation facility. "We are pleased to support FSSB and Sunview Group in this initiative. Looking ahead, we remain committed to strengthening our contribution to Malaysia's renewable energy ecosystem by exploring potential financing opportunities in upcoming government programmes,' AmBank Group managing director, business banking Christopher Yap said. Meanwhile, Sunview group executive director and group chief executive officer HP Ong said: 'The financing facilities provided play an important role in supporting the rollout of our solar project under the CGPP scheme. With this support, we are able to continue contributing to Malaysia's energy transition and contribute to a greener and more sustainable future.'
The Star
27-05-2025
- Business
- The Star
Sentral-REIT buys retail units for RM70mil
PETALING JAYA: Sentral Real Estate Investment Trust (Sentral-REIT) is acquiring 38 stratified retail units and 1,432 car park bays as part of the Arcoris Plaza Development from UEM Sunrise Bhd for RM70mil. In a filing with Bursa Malaysia, Sentral-REIT said the property is strategically located in Mont Kiara, Kuala Lumpur. 'Sentral-REIT will be able to take advantage of greater economies of scale in the Mont Kiara neighbourhood with the purchase of the property. 'This enables the company to leverage its existing resources (property management and leasing team) to manage the operations at the property.' Sentral-REIT said the prospects of the property are expected to be positive in view of its strategic location, good accessibility and steady income stream.
The Star
27-05-2025
- Business
- The Star
Sentral REIT acquires retail units in Mont Kiara for RM70mil
PETALING JAYA: Sentral Real Estate Investment Trust (Sentral REIT ) is acquiring 38 stratified retail units and 1,432 car park bays as part of the Arcoris Plaza Development from UEM Sunrise Bhd for RM70mil. In a filing with Bursa Malaysia, Sentral REIT said the property is strategically located in Mont Kiara, Kuala Lumpur. 'Mont Kiara is a mature neighbourhood with a large expatriate population, and it fulfils the criteria of a strategic location with good infrastructure, reputable international schools, bustling commercial centres, entertainment and leisure facilities. 'Sentral REIT will be able to take advantage of greater economies of scale in the Mont Kiara neighborhood with the purchase of the property. This enables the company to leverage its existing resources (property management and leasing team) to manage the operations at the property.' Sentral REIT said the prospects of the property are expected to be positive in view of its strategic location, good accessibility, good income stream. 'Premised on the above, the manager believes that the property will add value to the unitholders in the long run.'
The Star
22-05-2025
- Business
- The Star
Duopharma aiming for big govt insulin tender
Duopharma group managing director Leonard Ariff Abdul Shatar. KLANG: Duopharma Biotech Bhd is hoping to secure a sizeable contract to supply insulin to the Health Ministry (MoH) in the near term, which will help propel its growth. 'The significant jump (in contract value) has already occurred based on the announcements we made. I think we've announced all the significant jumps that we can foresee (for now). 'The next significant one will be the results of the insulin tender. That will be sizeable enough for us to make an announcement,' said group managing director Leonard Ariff Abdul Shatar. 'Our extension goes on till the end of October. While the tender (process) started (in May), I must caution that MoH traditionally for insulin always gives the contract to two parties. 'If only one party bids, MoH will wait until there's capability for a second party to bid,' he told reporters after the company's AGM yesterday. Its wholly-owned subsidiary, Duopharma Marketing Sdn Bhd, and India Biocon Ltd's local unit, Biocon Sdn Bhd, recently secured a six-month contract extension from MoH for the supply of insulin to public hospitals. Duopharma said the latest extended agreement is effective from April 29 until Oct 28, 2025. While the contract value was not disclosed in the filing, Leonard Ariff estimated the value of the six-month extension to be worth between RM30mil and RM35mil, about half of the annualised value of RM60mil to RM70mil. Duopharma, in which Yayasan Pelaburan Bumiputra holds a 44.11% stake, was awarded contracts totalling RM684.15mil to supply a combined total of 100 pharmaceutical and non-pharmaceutical products to healthcare facilities operated by the government, until Dec 31, 2026. The contracts are for products listed under the MoH's Approved Products Purchase List. Meanwhile, Leonard Ariff aims to increase the company's export business, which accounted for around 8% of its revenue in 2024, focusing on Asean countries mainly due to familiarity with regulatory environments and sizable markets. The company operates in about 30 markets, but its primary focus remains on Asean, as countries like Indonesia, the Philippines, Vietnam, Singapore, Brunei, and Thailand represent a significant portion of the global market, he explained. He added that Duopharma has made inroads into Timor-Leste, having won a government tender to supply halal pharmaceuticals. However, he expects higher demand for halal pharmaceuticals from Indonesia compared to Qatar and other Middle Eastern markets, which are still in the early stages. He said Indonesia is moving towards implementing a law, originally slated for 2022 or 2023, that mandates halal certification for over-the-counter pharmaceutical products. 'They have delayed its implementation to 2026 or 2027. That would be a more viable opening for Duopharma products, rather than the Middle East,' Leonard Ariff explained. The main focus for Duopharma this year will be on removing the bottleneck at its facilities in Klang and Bangi, Selangor, to cater to the needs of both the public and private sectors, ensuring its production capacity aligns with demand. 'We have more than enough capacity for the public sector. It is all about balancing (demand from the public and private sectors). We do not want to put all our eggs in one basket,' he said.
